Connect with us
US FDA Approves Novartis’ Fabhalta for IgA Nephropathy, Showing 44% Reduction in Urine Protein Levels.
The FDA's approval of the Shield blood test gives a new screening option for the colon cancer, but it still needs to follow-up colonoscopies to confirm...